icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 16-03 - RECRUITMENT CLOSED

STUDY TITLE

A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.

 

STUDY DESIGN

Multicentre, open label, randomised phase 2 study

 

CORRELATIVE STUDIES

Samples of blood and bone marrow are collected for additional studies into natural killer cell response to therapy and biomarker analysis

 

TRIAL PRINCIPAL INVESTIGATOR

Associate Professor Peter Mollee

 

TIME FRAME

2017 – 2021

 

PARTICIPANTS

120 newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant

 

CURRENT ENROLLMENT

120

 

STATUS

Closed to recruitment 

 

SITE LOCATIONS